Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfanilamide is a synthetic sulfonamide antibacterial drug and one of the earliest antibiotics developed. It acts as a competitive inhibitor of the bacterial enzyme dihydropteroate synthase, blocking the use of para-aminobenzoic acid (PABA) in folic acid synthesis. This inhibition prevents bacteria from synthesizing folic acid, which is essential for their growth and replication. Sulfanilamide was historically significant in reducing infection-related mortality during World War II but is now rarely used systemically due to toxicity and the availability of more effective alternatives. Today, it is primarily used topically or intravaginally for infections such as vulvovaginal candidiasis caused by Candida albicans[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfanilamide.